Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
1(20.0%)
N/A
1(20.0%)
5Total
Phase 1(3)
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06564623Phase 1Recruiting

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Role: collaborator

NCT06450210Phase 1Recruiting

Safety for Home Administration of Microdose Psilocybin Use

Role: collaborator

NCT06411691Phase 1Recruiting

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Role: collaborator

NCT04601038Phase 2Recruiting

Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)

Role: collaborator

NCT05386719Not ApplicableRecruiting

Cardiometabolic Screening Program

Role: collaborator

All 5 trials loaded